ArticleAntimicrobial agents and chemotherapy2006
Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 65 citations in OpenAlex.
- Monkeypox: Origin, Transmission, Clinical Manifestations, Prevention, and Therapeutic Options.Interdisciplinary perspectives on infectious diseases · 2025Review
- Large Subunit of the Human Herpes Simplex Virus Terminase as a Promising Target in Design of Anti-Herpesvirus Agents.Molecules (Basel, Switzerland) · 2023Article
- Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-Emerging Human Monkeypox Virus.Journal of microbiology and biotechnology · 2023Review
- An acyclic phosphonate prodrug of HPMPC is effective against VZV in skin organ culture and mice.Antiviral research · 2022Article
- Introduction of a cyano group at the 2-position of an (RSC medicinal chemistry · 2021Article
- Pressurized DNA state inside herpes capsids-A novel antiviral target.PLoS pathogens · 2020Article
- Drug Development against Smallpox: Present and Future.Antimicrobial agents and chemotherapy · 2020Review
- Novel Therapeutics for Epstein⁻Barr Virus.Molecules (Basel, Switzerland) · 2019Review
- Antiviral Therapies for Herpesviruses: Current Agents and New Directions.Clinical therapeutics · 2018Review
- Efficacy of N-methanocarbathymidine against genital herpes simplex virus type 2 shedding and infection in guinea pigs.Antiviral chemistry & chemotherapy · 2015Article
- Highlights in antiviral drug research: antivirals at the horizon.Medicinal research reviews · 2013Review
- Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.Antimicrobial agents and chemotherapy · 2013Article
- Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activity.Pharmaceutical research · 2013Article
- Human cytomegalovirus UL97 kinase alters the accumulation of CDK1.The Journal of general virology · 2012Article
- A nucleotide-analogue-induced gain of function corrects the error-prone nature of human DNA polymerase iota.Journal of the American Chemical Society · 2012Article
- Orthopoxvirus targets for the development of new antiviral agents.Antiviral research · 2012Review
- N-Methanocarbathymidine is more effective than acyclovir for treating neonatal herpes simplex virus infection in guinea pigs.Antiviral research · 2011Article
- Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Antimicrobial agents and chemotherapy · 2011Article
- CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.Antimicrobial agents and chemotherapy · 2011Article
- Treatment of herpes simplex virus infections in pediatric patients: current status and future needs.Clinical pharmacology and therapeutics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
N-Methanocarbathymidine [(N)-MCT] is a conformationally locked nucleoside analog that is active against some herpesviruses and orthopoxviruses in vitro. The antiviral activity of this molecule is dependent on the type I thymidine kinase (TK) in herpes simplex virus and also appears to be dependent on the type II TK expressed by cowpox and vaccinia viruses, suggesting that it is a substrate for both of these divergent forms of the enzyme. The drug is also a good inhibitor of viral DNA synthesis in both viruses and is consistent with inhibition of the viral DNA polymerase once it is activated by the viral TK homologs. This mechanism of action explains the rather unusual spectrum of activity, which is limited to orthopoxviruses, alphaherpesviruses, and Epstein-Barr virus, since these viruses express molecules with TK activity that can phosphorylate and thus activate the drug. The compound is also effective in vivo and reduces the mortality of mice infected with orthopoxviruses, as well as those infected with herpes simplex virus type 1 when treatment is initiated 24 h after infection. These results indicate that (N)-MCT is active in vitro and in vivo, and its mechanism of action suggests that the molecule may be an effective therapeutic for orthopoxvirus and herpesvirus infections, thus warranting further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.